A recent RCT set out to determine the safety and tolerability of ipragliflozin in combination with metformin on lowering glucose in patients with type 2 diabetes. The study also looked at the pharmacokinetic (PK) properties of metformin.
The updated recommendations are in response to a previous published article on aspirin therapy released in 2011. The current 2013 guideline recommendations by the ADA suggest aspirin therapy for primary prevention in patients with either type 1 or 2 diabetes who have an increased risk of cardiovascular disease.
GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan.
DV-0100 is proprietary, novel and safe. The therapy halts the body’s autoimmune reaction against the pancreatic islet cells which are responsible for producing insulin, allowing them to produce insulin normally and reversing the trajectory of the disease.
SGLT2 inhibitors act by blocking the kidneys’ reabsorption of sugar, or glucose. The result is that more glucose is released in the urine and the patient’s blood glucose level goes down — a major goal of diabetes treatment.
Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine. That differs from older drugs that decrease the amount of sugar absorbed from food and stored in the liver.
DPP-4 inhibitors, such as Januvia and Onglyza, now account for 21 percent of treatments. Long-acting insulins, such as Lantus and Levemir, also saw an increase from nearly negligible in 1997 to 18 percent in 2012. Short-acting insulins, like Novolog, Humalog, and Apidra, have increased modestly.
The researchers looked at three different outcomes to determine the impact of gender on response to diabetes therapies specifically as it relates to heart health.
Getting and keeping your cholesterol in good range is one of the ABC’s for diabetes control (A1C and blood pressure are the other two). As with glucose control, lifestyle management is the foundational step of any program emphasizing heart health.
Which is better, adding medications one at a time or all at once? It’s a question physicians will be pondering as they discuss the results of an ongoing study into how to dose oral medications for people with type 2 diabetes.
Why is Metformin considered the “starter” medicine for people who have been newly diagnosed with diabetes? Here are some of the benefits of this drug.
A recent study found that those taking metformin to help control blood glucose were 20 percent less likely to develop dementia over the course of the five-year study than those who were taking sulfonylureas to control their diabetes symptoms instead
The drug saxagliptin (trade name: Onglyza) has been approved also as monotherapy in Germany since July 2013 for certain adults with type 2 diabetes mellitus. It is an option when drug treatment is needed, but the drug metformin is not tolerated or cannot be used.
Over the past 15 years there have been dramatic changes in both what drugs are prescribed and how they are used in treating type 2 diabetes. A lot of this is a result of the new classes of drugs that have been developed. Other changes include the types of combination therapies and the rate at […]
The latest guidelines from American Heart and the American College of Cardiology indicate that anyone with Type 1 or 2 diabetes should be on cholesterol-lowering statins. Do you have to follow this recommendation even if your cholesterol is not high?
Both metformin and MK2 inhibitors work by targeting the liver, but the way they each work is different and this, the researchers say, is key as it means that the benefits of MK2 inhibitors can build upon the benefits of metformin.
An advisory panel voted in June to recommend loosening restrictions put in place in 2010, when the FDA limited Avandia use to patients with type 2 diabetes who could not control their illness with other medications.
The results from these studies show that ACE inhibitors significantly decreased the doubling of creatinine compared with placebo (OR=0.58; 95% credible interval, 0.32-0.9), and the use of beta-blockers significantly increased mortality risk (OR=7.13; 95% credible interval, 1.37-41.39).
In what’s being called a tectonic shift in the way doctors will treat high cholesterol, the American Heart Association and the American College of Cardiology on Tuesday released new treatment guidelines calling for a focus on risk factors rather than just cholesterol levels.
There are new drugs in diabetes town. The SGLT2 inhibitors work in the kidneys. They cause glucose to leave the body through the urine. Presto — blood glucose comes down. Could there be any disadvantages to this approach?